Trevi Therapeutics (TRVI)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.30 (+11.54%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Trevi Therapeutics (TRVI)
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Key Insights

Critical company metrics and information
  • Share Price

    $2.76
  • Market Cap

    $212.15 Million
  • Total Outstanding Shares

    76.87 Million Shares
  • Total Employees

    27
  • Dividend

    No dividend
  • IPO Date

    May 3, 2019
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.trevitherapeutics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities, Continuing$-35.06 Million
Net Cash Flow From Financing Activities, Continuing$9.96 Million
Net Cash Flow From Investing Activities$15.19 Million
Net Cash Flow From Financing Activities$9.96 Million
Net Cash Flow, Continuing$-9.91 Million
Net Cash Flow From Operating Activities$-35.06 Million
Net Cash Flow$-9.91 Million
Net Cash Flow From Investing Activities, Continuing$15.19 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Available To Common Stockholders, Basic$-44.32 Million
Research and Development$36.57 Million
Operating Income/Loss$-48.21 Million
Basic Earnings Per Share$0.44
Operating Expenses$48.21 Million
Revenues$0.00
Income/Loss From Continuing Operations Before Tax$-44.34 Million
Diluted Average Shares$100.77 Million
Preferred Stock Dividends And Other Adjustments$0.00
Income Tax Expense/Benefit$28000.00
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Diluted Earnings Per Share$0.44
Net Income/Loss$-44.32 Million
Income/Loss From Continuing Operations After Tax$-44.32 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss Attributable To Parent$-44.32 Million
Other Operating Expenses$11.65 Million
Nonoperating Income/Loss$3.87 Million
Basic Average Shares$100.77 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Accounts Payable$1.61 Million
Assets$68.91 Million
Other Non-current Assets$1.40 Million
Other Current Assets$66.16 Million
Liabilities And Equity$68.91 Million
Equity Attributable To Noncontrolling Interest$0.00
Current Liabilities$9.12 Million
Current Assets$67.34 Million
Equity$58.97 Million
Liabilities$9.94 Million
Equity Attributable To Parent$58.97 Million
Noncurrent Liabilities$816000.00
Other Current Liabilities$7.51 Million
Prepaid Expenses$1.18 Million
Fixed Assets$174000.00
Noncurrent Assets$1.57 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.